510(k) device
Panther Fusion SARS-CoV-2/Flu A/B/RSV assay
Hologic, Inc. · Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF, Class II) · First FDA decision May 16, 2023, newest Nov 15, 2024COVID-19, flu and respiratory infections
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
510(k) pathway
Device trials
2
Naming "Panther Fusion"
MAUDE reports
78
Brand "Panther Fusion", since 2015
PubMed studies
85
Mentioning "Panther Fusion"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Panther Fusion SARS-CoV-2/Flu A/B/RSV assay
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
K242465 · Decided Nov 15, 2024 · 87 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on DialysisNational analysisReview closedCAG-00413NUpdated Sep 17, 2026
- Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing AgentsNational determinationOn the books150.7Updated Aug 17, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Panther Fusion", any status and sponsor, newest update first.
Lucira Health IncNot on our public-company list
NCT04720235 · 304 participants · Start Dec 9, 2020 · Primary completion Mar 9, 2021
Device: Lucira COVID-19 All-In-One test kit · For: Covid19; Corona Virus Infection
Sites: Los Gatos, California
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Panther Fusion", and for the whole product code for context.
This brand
78 reports: 73 malfunction, 5 injury, 0 death
Whole product code QOF
56 reports: 48 malfunction, 8 injury, 0 death
Newest reports for this brand
2024800-2025-00003 · Received Jan 13, 2025 · Event dated Dec 14, 2024
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF)
Device problem as coded: Imprecise or Erratic Results; Device Contaminated at the User Facility
Patient problem as coded: Insufficient Information; No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay, REF: PRD-07400Open, Classified
Z-0694-2025 · Started Nov 8, 2024 · Posted by FDA Dec 20, 2024
Reason given: SARS-CoV-2/Flu A/B/RSV Assay Kit may erroneously produce SARS-CoV-2 false positive results.
Cause as FDA categorized it: Unknown/Undetermined by firm · Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF)
Published research
The most relevant PubMed records for "Panther Fusion"[tiab]. The summary above synthesizes these.
- Torquetenovirus Viremia Quantification Using Real-Time PCR Developed on a Fully Automated, Random-Access Platform.
Spezia PG, Carletti F, Novazzi F, et al. · Viruses · 2024Research Support, Non-U.S. Gov't
- Pooled Saliva Specimens for SARS-CoV-2 Testing.
Barat B, Das S, De Giorgi V, et al. · J Clin Microbiol · 2021Research Support, N.I.H., Intramural
- Comparative evaluation of Panther Fusion and real-time PCR for detection of Burkholderia pseudomallei in spiked human blood.
Gassiep I, Bauer MJ, Page M, et al. · Access Microbiol · 2022
- Evaluation of the Hologic Panther Fusion investigational use only assays for gastrointestinal bacterial pathogens.
Yakubu RR, Merwede J, Viglione B, et al. · J Clin Microbiol · 2025Evaluation Study, Research Support, Non-U.S. Gov't
- Pooled Saliva Specimens for SARS-CoV-2 Testing.
Barat B, Das S, De Giorgi V, et al. · medRxiv · 2020Preprint
- Performance evaluation of the Panther Fusion® respiratory tract panel.
Voermans JJC, Mulders DGJC, Pas SD, et al. · J Clin Virol · 2020Evaluation Study, Research Support, Non-U.S. Gov't
- Panther Fusion® Respiratory Virus Assays for the detection of influenza and other respiratory viruses.
Stellrecht KA, Cimino JL, Wilson LI, et al. · J Clin Virol · 2019Evaluation Study, Research Support, Non-U.S. Gov't
- Multi-center clinical evaluation of the Panther Fusion SARS-CoV-2/Flu A/B/RSV assay in nasopharyngeal swab specimens from symptomatic individuals.
Sasidharan A, Selvarangan R, Konrad K, et al. · J Clin Microbiol · 2023Research Support, U.S. Gov't, Non-P.H.S.
- Comparison of the Panther Fusion respiratory panels to routine methods for detection of viruses in upper and lower respiratory tract specimens.
Boerger AC, Binnicker MJ · Diagn Microbiol Infect Dis · 2020Comparative Study, Evaluation Study
- Development of real-time RT-PCR assays to detect measles virus on the Hologic Panther Fusion® System.
Grant J, Atapattu N, Dilcher M, et al. · J Clin Virol · 2023
- The Panther Fusion System with Open Access Functionality for Laboratory-Developed Tests for Influenza A Virus Subtyping.
Stellrecht KA, Cimino JL, Maceira VP · J Clin Microbiol · 2020Research Support, Non-U.S. Gov't
- Multicenter Evaluation of the Cepheid Xpert GBS LB XC Test.
Thwe PM, Faron ML, Pride DT, et al. · J Clin Microbiol · 2022Multicenter Study, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code QOF.
- Xpert Xpress CoV-2/Flu plusCepheid® · 510(k) 2026
- BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel MiniBiofire Diagnostics, LLC · 510(k) 2025
- QIAstat-Dx Respiratory Panel PlusQIAGEN GmbH · 510(k) 2025
- BIOFIRE Respiratory Panel 2.1 (RP2.1)Biofire Diagnostics · De Novo 2026
- FINDER Flu A&B/SARS-CoV-2 TestBaebies, Inc. · 510(k) 2026
- Simplexa COVID-19/ Flu A/B & RSV Direct (MOL4450)Diasorin Molecular, LLC · 510(k) 2025
- cobas Respiratory 4-flex for use on the cobas 5800/6800/8800 SystemsRoche Molecular Systems, Inc. · 510(k) 2025
- cobas liat SARS-CoV-2 & Influenza A/B v2 nucleic acid testRoche Molecular Systems, Inc. · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.